Evidence map›Paper›PMID 38905267›Full record

SynthesisPloS one2024

The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.

Bingjia Qu, Feng Zhao, Ying Song, Junyi Zhao, Yuxin Yao, Yulan Chen, Ruobing Liao, Lingyu Fu

Abstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bingjia QuDepartment of Clinical Epidemiology and Evidence-based medicine, The First Hospital, China Medical University, Shenyang, China.
Feng ZhaoDepartment of Clinical Epidemiology and Evidence-based medicine, The First Hospital, China Medical University, Shenyang, China.
Ying SongDepartment of Clinical Epidemiology and Evidence-based medicine, The First Hospital, China Medical University, Shenyang, China.
Junyi ZhaoDepartment of Clinical Epidemiology and Evidence-based medicine, The First Hospital, China Medical University, Shenyang, China.
Yuxin YaoDepartment of Clinical Epidemiology and Evidence-based medicine, The First Hospital, China Medical University, Shenyang, China.
Yulan ChenDepartment of Clinical Epidemiology and Evidence-based medicine, The First Hospital, China Medical University, Shenyang, China.
Ruobing LiaoDepartment of Clinical Epidemiology and Evidence-based medicine, The First Hospital, China Medical University, Shenyang, China.
Lingyu FuDepartment of Clinical Epidemiology and Evidence-based medicine, The First Hospital, China Medical University, Shenyang, China.ORCID 0000-0001-5854-7007

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to evaluate the efficacy and safety of JAK inhibitors in the treatment of patients with RA.

methodsThe databases CNKI, VIP, Wanfang, CBM, and PubMed, Embase, Cochrane Library and Web of Science were searched to identify relevant randomized controlled trials (RCTs), all from the time of database creation to April 2024. Screening, data extraction, and risk of bias assessment (using Review Manager-5.3 software) were independently performed by at least two authors. The network meta-analysis was conducted using R 4.1.3 software. PROSPERO registration number: CRD42022370444.

resultsThirty-three RCTs included 15,961 patients The experimental groups involved six JAK inhibitors (filgotinib, tofacitinib, decernotinib, baricitinib, upadacitinib and peficitinib) and 12 interventions (different doses of the six JAK inhibitors), and the control group involved adalimumab (ADA) and placebo. Compared with placebo, all JAK inhibitors showed a significant increase in efficacy measures (ACR20/50/70). Compared with ADA, only tofacitinib, low-dose decernotinib, and high-dose peficitinib showed a significant increase in ACR20/50/70. Decernotinib ranked first in the SUCRA ranking of ACR20/50/70. In terms of safety indicators, only those differences between low-dose filgotinib and high-dose upadacitinib, low-dose tofacitinib and high-dose upadacitinib were statistically significant. Low-dose filgotinib ranked first in the SUCRA ranking with adverse events as safety indicators. Only the efficacy and safety of tofacitinib ranked higher among different SUCRA rankings.

conclusionSix JAK inhibitors have better efficacy than placebo. The superior efficacy of decernotinib and safety of low-dose filgotinib can be found in the SUCRA. However, there are no significant differences in safety between the different JAK inhibitors. Head-to-head trials, directly comparing one against each other, are required to provide more certain evidence.

Indexed as

Arthritis, RheumatoidAzetidinesBayes TheoremJanus Kinase InhibitorsPiperidinesPyrimidinesAdamantaneAntirheumatic AgentsBenzamidesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, 3-RingHumansNiacinamidePurinesPyrazolesPyridines2-((2-(1H-pyrrolo(2,3-b)pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamideAdamantaneAntirheumatic AgentsAzetidinesbaricitinibBenzamidesGLPG0634Heterocyclic Compounds, 2-RingHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsN-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamideNiacinamidepeficitinibPiperidinesPurinesPyrazolesPyridinesPyrimidinesPyrrolesSulfonamidestofacitinibTriazolesupadacitinibValine

Identifiers

PMID38905267
PMCPMC11192398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.